Implication of calcium activated RasGRF2 in Annexin A6-mediated breast tumor cell growth and motility

Area of Science:

• Oncology
• Molecular Biology
• Cell Biology

Background:

• The precise role of Annexin A6 (AnxA6) in breast cancer progression, particularly triple-negative breast cancer (TNBC), is not fully understood.
• Mechanisms linking AnxA6 to tumor cell growth and motility require elucidation.

Purpose of the Study:

• To investigate the tumor suppressor function of AnxA6 in TNBC.
• To identify AnxA6-mediated effectors involved in TNBC cell growth and motility.
• To explore potential therapeutic targets for AnxA6-modulated TNBC.

Main Methods:

• Xenograft tumor models in mice to assess AnxA6's role in tumor onset and growth.
• Investigated the interaction between AnxA6, calcium (Ca2+), and RasGRF2 signaling pathways.
• Utilized pharmacological inhibitors (e.g., lapatinib) and genetic manipulation (overexpression/down-regulation) to study pathway modulation.

Main Results:

• Loss of AnxA6 correlated with early onset and rapid growth of TNBC xenografts.
• Identified Ca2+-activated RasGRF2 as a key effector in AnxA6-mediated TNBC cell growth and motility.
• AnxA6 functions as a scaffold for RasGRF2 and Ras proteins, with interactions modulated by GTP and Ras activation.
• Inhibition of Ca2+ influx or AnxA6 overexpression prevented RasGRF2 activation/degradation.
• Down-regulation of RasGRF2 and lapatinib treatment reduced growth in AnxA6-high TNBC cells, including resistant cases.

Conclusions:

• AnxA6 modulates Ca2+ influx and RasGRF2 effector functions, contributing to TNBC cell growth and motility.
• AnxA6's interaction with RasGRF2 is crucial for regulating TNBC cell behavior.
• Targeting Ras-driven TNBC with combined EGFR-targeted therapies and RasGRF2 inhibition presents a promising therapeutic strategy.